Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

• Asıl Yazarlar: CH Spencer (Yazar), K Rouster-Stevens (Yazar), H Gewanter (Yazar), G Syverson (Yazar), R Modica (Yazar), K Schmidt (Yazar), H Emery (Yazar), C Wallace (Yazar), S Grevich (Yazar), K Nanda (Yazar), YD Zhao (Yazar), S Shenoi (Yazar), S Tarvin (Yazar), S Hong (Yazar), C Lindsley (Yazar), JE Weiss (Yazar), M Passo (Yazar), K Ede (Yazar), A Brown (Yazar), K Ardalan (Yazar), W Bernal (Yazar), ML Stoll (Yazar), B Lang (Yazar), R Carrasco (Yazar), C Agaiar (Yazar), L Feller (Yazar), H Bukulmez (Yazar), R Vehe (Yazar), H Kim (Yazar), H Schmeling (Yazar), D Gerstbacher (Yazar), M Hoeltzel (Yazar), B Eberhard (Yazar), R Sundel (Yazar), S Kim (Yazar), AM Huber (Yazar), A Patwardhan (Yazar), Pediatric Rheumatologist Collaborators (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BMC, 2017-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Background The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics...